Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Core Insights - Myriad Genetics has received two new patents from the United States Patent and Trademark Office, enhancing its capabilities in bringing its tumor-informed, high-definition molecular residual disease (MRD) assay to market [1] - In 2024, Myriad was awarded three patents related to foundational MRD technology and cell-free DNA preparation methods, which enable highly sensitive and specific sequencing-based MRD assays [2] - The company emphasizes that its Precise MRD assay addresses critical questions in cancer treatment, specifically regarding treatment efficacy and cancer recurrence [3] Company Overview - Myriad Genetics is a leader in genetic and tumor genomic testing, focusing on precision medicine to improve health outcomes and reduce healthcare costs [5] - The Precise MRD test utilizes whole-genome sequencing to analyze hundreds to thousands of targeted variants, allowing for sensitive detection of low tumor levels [4] - The company is actively developing its Precise MRD assay in collaboration with academic partners and biopharma companies, with ongoing evaluations in high-impact studies [3][4] Patent Details - The newly issued patents include US patent No. 12,215,391, which pertains to automated methods of MRD analysis, and US patent No. 12,215,392, which relates to patient journey aspects of MRD [7]